01.10.2012 22:30
Bewerten
(0)

Elan Announces Redemption of Its Senior Notes Due 2016

Elan Corporation, plc ("Elan”) (NYSE: ELN) announced today that it will redeem all of the Senior Notes due 2016 issued on October 2, 2009 (the "2009 Notes”) and Senior Notes due 2016 issued on August 17, 2010 (the "2010 Notes” and, together with the 2009 Notes, the "Notes”) of its wholly owned subsidiaries, Elan Finance public limited company and Elan Finance Corp. (the "Co-Issuers”), that remain outstanding following the completion of the Co-Issuers’ previously announced tender offer to purchase any and all of the outstanding Notes (the "Tender Offer”). The Tender Offer is made pursuant to an Offer to Purchase and Consent Solicitation Statement (the "Offer to Purchase and Consent Solicitation Statement”), dated September 24, 2012, and will expire at 11:59 p.m., Eastern Time, on October 22, 2012, unless the Tender Offer is extended or earlier terminated (the "Expiration Date”). Notes in an aggregate principal amount of $624.5 million are currently outstanding.

The Notes are redeemable at the Co-Issuers’ option at a redemption price equal to 108.750% of the outstanding principal amount (i.e., $1,087.50 per $1,000 principal amount of the Notes), plus an amount equal to $3.89 per $1,000 principal amount, which represents the accrued but unpaid interest from October 15, 2012, the most recent interest payment date of the Notes, to October 31, 2012. The redemption is expected to occur on October 31, 2012.

Under the terms of the Tender Offer, holders of the Notes who validly tender and do not withdraw their Notes prior to 11:59 p.m., Eastern Time, on October 5, 2012 (as such time and date may be extended, the "Consent Payment Deadline”) and whose Notes are accepted for purchase, will receive the "Total Consideration,” which is equal to (i) $1,053.34 per $1,000.00 principal amount of Notes validly tendered (the "Tender Offer Consideration”) plus (ii) a consent payment of $40.00 per $1,000.00 principal amount of Notes validly tendered. Holders of Notes who validly tender their Notes after the Consent Payment Deadline but on or before the Expiration Date, and whose Notes are accepted for purchase, will receive only the Tender Offer Consideration. In addition to the Total Consideration or the Tender Offer Consideration, holders whose Notes are accepted in the Tender Offer will receive accrued and unpaid interest from and including the most recent interest payment date, and up to, but excluding, the applicable settlement date.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

Safe Harbor/Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.

The information contained in this press release is not for publication or distribution in Canada, Australia or Japan and does not constitute an offer of securities for sale in Canada, Australia or Japan.

In the United Kingdom, this press release is directed only at (i) Persons who have professional experience in matters relating to investments falling within Article 19(1) of The Financial Services And Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (ii) High Net Worth Entities falling within Article 49(2) of The Order and (iii) persons to whom it would otherwise be lawful to distribute it (all such persons together being referred to as "Relevant Persons").

In addition, if and to the extent that this press release is communicated in any EEA member state that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any member state, the "Prospectus Directive”), this press release is only addressed to and directed at persons in that member state who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that member state. This press release does not constitute a prospectus within the meaning of the Prospectus Directive. This press release constitutes an advertisement for the purposes of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (as amended).

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the completion of the Tender Offer and Consent Solicitation. You can identify these statements by the fact that they use words such as "expect”, "estimate”, and "intend” and other words and terms of similar meaning in connection with any discussion of future events. Factors that could affect whether the Tender Offer and Consent Solicitation is completed include, among other things, uncertainties related to corporate debt securities generally, the securities of biotechnology companies generally and Elan’s debt securities in particular. A further list and description of risks, uncertainties and other matters can be found in Elan’s Annual Report on Form 20-F for the fiscal year ended December 31, 2011 and in its Reports of Foreign Issuer on Form 6-K furnished to the Securities and Exchange Commission. Elan assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

SOURCE: Elan Corporation, plc:

Nachrichten zu Elan Corporation PLC (spons. ADRs)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Analysen zu Elan Corporation PLC (spons. ADRs)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
08.08.2012Elan neutralExane-BNP Paribas SA
02.08.2012Elan outperformRBC Capital Markets
26.07.2012Elan neutralExane-BNP Paribas SA
26.07.2012Elan neutralUBS AG
23.07.2012Elan outperformRBC Capital Markets
02.08.2012Elan outperformRBC Capital Markets
23.07.2012Elan outperformRBC Capital Markets
22.06.2012Elan outperformRBC Capital Markets
14.06.2012Elan buyJefferies & Company Inc.
28.03.2012Elan outperformRBC Capital Markets
08.08.2012Elan neutralExane-BNP Paribas SA
26.07.2012Elan neutralExane-BNP Paribas SA
26.07.2012Elan neutralUBS AG
27.04.2012Elan neutralExane-BNP Paribas SA
13.01.2011Elan neutralUBS AG
21.07.2010Elan reduceGoodbody Stockbrokers
16.07.2010Elan "reduce"Goodbody Stockbrokers
02.08.2006Update Elan Corporation plc (Spons. ADRs): UnderpePiper Jaffray
06.06.2006Update Elan Corporation plc (Spons. ADRs): UnderpePiper Jaffray
20.01.2006Update Elan Corporation plc (Spons. ADRs): UnderweLehman Brothers

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Elan Corporation PLC (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen

Meistgelesene Elan News

Keine Nachrichten gefunden.
Weitere Elan News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Aktien mit Sicherheit und Potenzial

Für die neue Ausgabe des Anlegermagazins haben unsere Redakteure Aktien identifiziert, die aus ihrer Sicht Sicherheit und Potenzial bieten. Einen besonderen Blick werfen sie dabei auf die Chemie- und Versicherungsbranche. Erfahren Sie im aktuellen Magazin, wie Sie "Richtig investieren" und lesen Sie, welche Aktien bei überschaubarem Risiko einiges an Potenzial bieten.
Anlegermagazin kostenlos erhalten

Elan Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX mit Verlust -- Dow leichter -- Deutsche Bank zahlt Millionen in Anleihen-Rechtsstreit -- STADA-Übernahme erfolgreich -- Verhandlungen über Zukunft von Air Berlin

Analyst ermittelt den perfekten Einstiegskurs für Bitcoins. Offizielle Bestätigung: Investor bietet Milliarden für Calpine. Busch bei Pfeiffer Vacuum mit neuem Etappensieg. Venezuelas Bolivar fällt auf Rekordtief. Unsicherheit beim iPhone 8: Wann kommt das neue Apple Smartphone? Commerzbank sieht sich beim Stellenabbau auf dem Weg.

Top-Rankings

KW 33: Analysten-Tops der Woche
Diese Aktien stehen auf den Kauflisten der Experten
Nicht nur schön und talentiert
Diese Frauen haben in Hollywood am meisten verdient
Diese Aktien hat Warren Buffett im Depot (Juni 2017)
Die Top-Positionen von Warren Buffett

Die 5 beliebtesten Top-Rankings

Enormer Stressfaktor
In diesen Ländern haben Arbeitnehmer den größten Stress
Der CEO von Allianz, BMW oder doch Daimler?
Diese Manager lieben die Deutschen
Das sind 2017 bislang die größten Verlierer in Buffetts Depot
Welche Aktie enttäuschte bisher am meisten?
Die Meister-Liste der 1. Fußball Bundesliga
Welcher Verein hat die meisten Meistertitel?
Bitcoin & Co.: Die wichtigsten Kryptowährungen
Welche Digitalwährung macht das Rennen?
mehr Top Rankings

Umfrage

Die Deutsche Bank wird optimistischer für deutsche Aktien und sieht beim DAX bis Jahresende noch 3 Prozent Luft nach oben. Was glauben Sie, wie sich der DAX bis zum Ende des Jahres entwickeln wird?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln

Willkommen bei finanzen.net Brokerage

Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus finanzen.net!

Weitere Informationen finden Sie hier.

Jetzt informieren und Depot eröffnen


Sie haben bereits ein Depot? Dann verknüpfen Sie es jetzt mit Ihrem finanzen.net-Account!

Jetzt verknüpfen

Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Volkswagen (VW) AG Vz.766403
Air Berlin plcAB1000
CommerzbankCBK100
Apple Inc.865985
EVOTEC AG566480
E.ON SEENAG99
AlibabaA117ME
TeslaA1CX3T
Nordex AGA0D655
Amazon906866
Allianz840400
Lufthansa AG823212
Bitcoin Group SEA1TNV9